Divi's Laboratories Ltd - Company Profile
Powered by 
All the sales intelligence you need on Divi's Laboratories Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Divi's Laboratories Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Divi's Laboratories Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Divi's Laboratories Ltd (Divi) is a pharmaceutical company. It manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. The company’s product portfolio consists of generic APIs, custom synthesis, and nutraceuticals. The company offers products that include bupropion HCl, diltiazem HCl, carbidopa, dextromethorphan HBr, gabapentin, irbesartan, lacosamide, naproxen sodium, quetiapine fumarate, triprolidine HCl, valacyclovir HCl, venlafaxine HCl, valsartan, and nutraceuticals including beta carotene, astaxanthin, lycopene, and canthaxanthin. Its extensive API portfolio consists of medications for various disease conditions, including cardiovascular, inflammation, cancer, and central nervous system treatments. It offers contract manufacturing services for APIs and intermediates of various compounds. It operates manufacturing plants in Hyderabad and Visakhapatnam, India. The company’s Generic APIs division has operations in over 100 countries. Divi is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
1-72/23(P)/Divis/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad, Telangana, 500032
Website
www.divislabs.com
Telephone
91 40 66966300
No of Employees
18,300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DIVISLAB (NSE)
Revenue (2025)
$1.1B
19.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
36.9%
(2025 vs 2024)
Market Cap*
$23.1B
Net Profit Margin (2025)
XYZ
14.8%
(2025 vs 2024)
* As of and is in US$
Divi's Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Commercialized: | Custom Synthesis: |
| Bupropion HCl | Contract Manufacturing Services |
| Capecitabine | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In April, the company entered into a manufacturing and supply agreement with a global pharmaceutical firm to deliver advanced intermediates. |
| 2024 | Plans/Strategy | In April, Divi’s Nutraceuticals announced its plans to introduce AstaBead. |
| 2024 | Plans/Strategy | In April, the company announced its plans to invest INR700 Crore to add more capacity at its manufacturing facility. |
Competitor Comparison
| Key Parameters | Divi's Laboratories Ltd | Biocon Ltd | Piramal Enterprises Ltd | Jubilant Pharmova Ltd | Granules India Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Bengaluru | Mumbai | Noida | Hyderabad |
| State/Province | Telangana | Karnataka | Maharashtra | Uttar Pradesh | Telangana |
| No. of Employees | 18,300 | 3,442 | 16,397 | 978 | 4,066 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Kiran S. Divi | Director; Chief Executive Officer | Executive Board | 2020 | - |
| Dr. Murali K. Divi, Ph.D. | Managing Director | Executive Board | 1990 | - |
| Manoranjan Jasti | Chief Information Officer | Senior Management | 2025 | - |
| Dr. Ramesh B.V. Nimmagadda | Chairman | Non Executive Board | 2020 | - |
| Dr. N.V. Ramana | Executive Director | Executive Board | 1994 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer